期刊名称：NEPHRON
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Nephron
The world of nephrology united in one publication
Aims and Scope
'Nephron' comprises three sections, which are each under the editorship of internationally recognized leaders and served by specialized Associate Editors. Apart from high-quality original research, 'Nephron' publishes invited reviews/minireviews on up-to-date topics. Papers undergo an innovative and transparent peer review process encompassing a Presentation Report which assesses and summarizes the presentation of the paper in an unbiased and standardized way.
The section Clinical Practice provides readers with up-to-date research and opinions on all aspects of clinical nephrology, dialysis and transplantation. Original articles report on innovative clinical studies and patient-based experimental work which has immediate relevance to clinical practice. Also included are clinical trial protocols which report on phase II trials and methodology studies. Second opinion articles provide a critical evaluation of published papers on hot topics in clinical and experimental nephrology as well as opinions on controversial topics.
The section Experimental Nephrology and Genetics specializes in the publication of original research, review articles and case studies of genetic interest in the field of basic science. Increasingly sophisticated technology and model organism variety have led to immense advances in the understanding of the pathophysiology of renal disease progression and repair, molecular targets and biomarkers, genetics of rare renal diseases, and the biology of stem cells. This section will be devoted to report cutting edge results in these areas.
The section Physiology covers the broad field of cellular and integrative function of the kidney and urinary tract in health and disease. For the first time, renal and urinary tract functions are brought together in scientific terms in order to bridge the basic sciences relevant to medicine, nephrology and urology. This section covers both normal physiology and pathophysiology of the kidney and serves as a vehicle for advancing knowledge on functional mechanisms of disease.
The open access journal 'Nephron Extra' provides additional contents based on reviewed and accepted submissions to the main journal 'Nephron' on www.karger.com/nne.
Bibliographic Details
Nephron
Journal Abbreviation: Nephron
ISSN: 1660-8151 (Print)
e-ISSN: 2235-3186 (Online)
DOI: 10.1159/issn.1660-8151
www.karger.com/NEF
Indexing/Abstracting
Listed in bibliographic services, including Journal Citation Reports, PubMed/MEDLINE, Biological Abstracts, Embase, Amedeo
History
Founded 1964 by G. Richet and G.E. Schreiner
From 2003 to 2014, Nephron was published online as three independent subjournals: Nephron Clinical Practice, Nephron Experimental Nephrology, and Nephron Physiology.
Former Editors: S. Giovannetti (1972–1998); G.M. Berlyne (1972–2002);
S. Ito (1998–2002); L.G. Fine (2003–2014)
Instructions to Authors
Guidelines for Authors
www.karger.com/nef_guidelines
Submission
Conditions
Conflicts of Interest
Ethics
Plagiarism Policy
Arrangement
Color Illustrations
References
Digital Object Identifier (DOI)
Supplementary Material
Self-Archiving/Green Open Access, Author's ChoiceTM,
Funding Organizations (NIH etc.)
Page Charges
Proofs
Reprints
Uniform Clinical Trial Registration Policy for Journals of
Kidney Diseases, Dialysis and Transplantation
Submission
Manuscripts in English should be submitted online:
Should you experience any problems with your submission, please contact the Managing Editor, Manuela Passera
manuela.passera@marionegri.it
Tel. +39 035 4213405
Fax +39 035 319331
Original papers: Submitted manuscripts should be fully documented reports of original research. They must describe significant and original observations to be critically evaluated and, if necessary, repeated.
Clinical trial protocols will only be considered if the trial has been fully registered (see A Uniform Clinical Trial Registration Policy for Journals of Kidney Diseases, Dialysis and Transplantation below).
Reviews/Minireviews: Are to be submitted only by invitation, although prospective authors are welcome to contact the Managing Editor to discuss whether a topic might be suitable for a Review. The maximum length of a Review/Minireview should be 3,500/2,000 words including abstract and discussion, excluding figure legends and references (50/25 references maximum).
Editorial and Second Opinion: The maximum length of an Editorial/Second Opinion article should be 1,500/2,500 words including abstract, integrated discussion, excluding references (25/40 references maximum).
Case studies of genetic interest: the objective of such papers in the section Experimental Nephrology and Genetics is to provide clinically relevant examples of the genetic heterogeneity of renal diseases. Therefore, reports of cases with an unusual genotype/phenotype correlation, or clinical pictures that revealed an unexpected genetic basis are welcome. Also, functional studies of genetic forms of renal diseases shedding light on the disease mechanism are appropriate for submission in this section. Outside this scope Nephron does not publish any case reports. The authors of case reports are invited to submit their manuscript to the Open Access journal Case Reports in Nephrology and Dialysis at www.karger.com/cnd.
Conditions and review
All manuscripts are subject to independent and editorial review.
Upon submission, each manuscript is evaluated by the editors and the authors are informed whether the manuscript will be further processed.
Before being forwarded to the Associate Editors and reviewers, the presentation of the paper (organization of the results, quality of the figures, overall writing quality, etc.) is assessed and summarized in a Presentation Report that is fair, professional and standardized. The Presentation Report follows the manuscript throughout the peer review and supports editors, reviewers, and authors in the review process.
The Editors and Associate Editors carefully analyse the comments of the reviewers in order to provide the authors with constructive and realistic requests that should be feasible within the 12 weeks of revision time. The requests made to the authors by the editors are aimed to improve the robustness and significance of the data presented in the manuscript, while curtailing excessive demands in term of effort, time and cost.
Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Nephron and may not be reproduced by any means, in whole or in part, without the written consent of the publisher.
It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.
Conflicts of Interest
Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the article.
Plagiarism Policy
Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation.
If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).
Ethics
Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute's committee on human research. Further, they should also state that animal experiments conform to institutional standards.
Arrangement
Title page: The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, a short title for use as running head (max. 80 characters), the word count and the total number of references.
Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone number and well as e-mail address.
Units: Nephron requires that all articles be submitted with data in SI units and gravimetric units.
Key words:Please supply 3–10 key words in English that reflect the content of the paper
Abstract: Each paper needs an abstract of up to 250 words. It should be structured as follows:
Background/Aims: What is the major problem that prompted the study?
Methods: How was the study carried out?
Results: Most important findings?
Conclusion: Most important conclusion?
Footnotes: Avoid footnotes.
Tables and illustrations: Tables are part of the text. Place them at the end of the text file. Illustration data must be stored as separate files. Do not integrate figures into the text. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi.
Color Illustrations
Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.
Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.00 per page.
References
In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as ‘unpublished data’ and not be included in the reference list. The list of references should include only those publications which are cited in the text. Number references in the order in which they are first mentioned in the text; do not list alphabetically. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).
|
Examples
(a) Papers published in periodicals:
Robinson CM, O’Dee D, Hamilton T, Nau GJ: Cytokines involved in interferon-γ production by human macrophages. J Innate Immun 2010;2:56–65.
(b) Papers published only with DOI numbers:
Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.
(c) Monographs:
Matthews DE, Farewell VT: Using and Understanding Medical Statistics, ed 3, revised. Basel, Karger, 1996.
(d) Edited books:
Kashihara N, Sugiyama H, Makino H: Implication of apoptosis in progression of renal diseases; in Razzaque MS, Taguchi T (eds): Renal Fibrosis. Contrib Nephrol. Basel, Karger, 2003, vol 139, pp 156–172.
|
Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.
Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org
Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).
Self-Archiving/Green Open Access
Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:
- Be used for noncommercial purposes only
- Be linked to the final version on www.karger.com
- Include the following statement:
‘This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number].’
It is the author’s responsibility to fulfill these requirements.
For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.
Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf [see Funding Organizations (NIH etc.)].
For self-archiving Author's ChoiceTM (Gold Open Access) articles, see Author's ChoiceTM.
Author's ChoiceTM
Karger’s Author's ChoiceTM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.
The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:
- Follow the terms of the relevant Creative Commons license
- Be linked to the final version on www.karger.com
- Include the following statement:
‘The final, published version of this article is available at http://www.karger.com/?doi=[insert DOI number].’
It is the author’s responsibility to fulfill these requirements.
For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.
Funding Organizations (NIH etc.)
The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author's ChoiceTM, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC.
Authors should include information on their grant in the Acknowledgements section of their papers.
Page Charges
There are no page charges for papers of 3 or fewer printed pages (including tables, figures, references and acknowledgements). Each additional complete or partial page is charged to the author at CHF 375.–.
Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer's errors are charged to the author.
Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
A Uniform Clinical Trial Registration Policy for Journals of Kidney Diseases, Dialysis and Transplantation
Clinical trials provide important information that can profoundly influence the direction of medical research and clinical care. It is crucial that this process is not unduly influenced by selective publication of clinical trial results. Information regarding all clinical trials should therefore be made available to the general public.
In common with other nephrology journals, Nephron requires that from 2006 all submitted manuscripts concerning clinical trials must be registered in a public trials registry.
The full text of a recent statement published by the editors of: Kidney International; The Journal of the American Society of Nephrology; Nephrology, Dialysis, Transplantation; The American Journal of Transplantation; The American Journal of Kidney Diseases, and Transplantation is reproduced below. The policy described in this text has now been formally adopted by Nephron.
Medical research can be seriously compromised by the selective publication of clinical trial results. Therefore, it is imperative that information regarding clinical trials should be available to the general public.
We require, as a condition of consideration for publication, registration in a public trials registry. Trials must register at or before the onset of patient enrolment. Since 1 April 2006, Nephron no longer accepts manuscripts concerning non-registered trials.
We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g. phase 1 trials) are exempt.
We do not advocate any one particular registry, but registration must be with a registry that meets the following minimum criteria:
- Accessible to the public at no charge.
- Searchable by standard, electronic (internet-based) methods.
- Open to all prospective registrants free of charge or at minimal cost.
- Validates registered information.
- Identifies trials with a unique number.
- Includes information on the investigator(s), research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow-up, target number of subjects, status (anticipated, ongoing or closed) and funding source(s).
Registries that currently meet these criteria include:
Editorial Board
Editor-in-Chief
A. Benigni, Bergamo
Managing Editor
M. Passera, Bergamo
Consulting Editor
G. Remuzzi, Bergamo
Clinical Practice
Section Editor
D.G. Warnock, Birmingham, Ala.
Associate Editors
M.H. de Borst, Groningen
C.P. Kovesdy, Memphis, Tenn.
A. Yee-Moon Wang, Hong Kong
Section Editor Second Opinion
C.-W. Yang, Taoyuan
Advisory Board Second Opinion
L. Gallon, Chicago Ill.
J.C. He, New York, N.Y.
K. Kalantar-Zadeh, Orange, Calif.
M. Nangaku, Tokyo
A.Y. Meyrier, Paris
G. Remuzzi, Bergamo
Experimental Nephrology and Genetics
Section Editors
F. Terzi, Paris
N.V.V.A.M. Knoers, Utrecht
Associate Editors
R. Coward, Bristol
J. Hoefele, Munich
F. Martin-Belmonte, Madrid
K. Osafune, Kyoto
Case Studies in Genetics
Marina Vivarelli, Rome
Physiology
Section Editor
F. Lang, Tübingen
Associate Editors
K.M. Boini, Richmond, Va.
B. Hocher, Potsdam-Nuthetal
V. Vallon, La Jolla, Calif.
C. Wagner, Zurich
|
